Analysts Set Inflarx NV (IFRX) Target Price at $42.67
Shares of Inflarx NV (NASDAQ:IFRX) have earned an average rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $42.67.
Several equities analysts recently issued reports on the stock. ValuEngine raised shares of Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research raised shares of Inflarx from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th.
Several institutional investors and hedge funds have recently made changes to their positions in IFRX. Matisse Capital acquired a new position in Inflarx during the third quarter worth approximately $203,000. Northern Trust Corp acquired a new position in Inflarx during the first quarter worth approximately $228,000. Bank of New York Mellon Corp acquired a new position in Inflarx during the third quarter worth approximately $277,000. Jane Street Group LLC acquired a new position in Inflarx during the third quarter worth approximately $278,000. Finally, JPMorgan Chase & Co. increased its position in Inflarx by 29.2% during the third quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock worth $367,000 after purchasing an additional 2,420 shares during the last quarter. 54.80% of the stock is currently owned by institutional investors and hedge funds.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
See Also: How to Use a Moving Average for Trading
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.